Andreas Wicki - Nov 15, 2021 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Role
Director
Signature
/s/ Mehdi Khodadad, Attorney-in-fact
Stock symbol
HRMY
Transactions as of
Nov 15, 2021
Transactions value $
-$2,881,693
Form type
4
Date filed
11/17/2021, 08:00 PM
Next filing
Dec 10, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Sale -$1.5M -35.6K -0.77% $42.08 4.61M Nov 15, 2021 See Footnote F1, F2
transaction HRMY Common Stock Sale -$1.33M -32.3K -0.7% $41.09 4.57M Nov 16, 2021 See Footnote F2, F3
transaction HRMY Common Stock Sale -$58.5K -1.42K -0.03% $41.25 4.57M Nov 17, 2021 See Footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.80 to $42.91, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.
F2 These shares are held by HBM Healthcare Investments (Cayman) Ltd. ("HBM"), of which Mr. Wicki is a member of the board of directors. The board of directors of HBM acts by majority vote, and Mr. Wicki does not have sole voting or investment power with respect to the shares. Mr. Wicki disclaims beneficial ownership of such shares for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purposes of Section 16 of the Exchange Act, or for any other purpose.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.08 to 41.09, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (3) of this Form 4.